Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Antibodies, Neutralizing"" wg kryterium: Temat


Tytuł :
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection.
Autorzy :
Winkler ES; Department of Medicine, Washington University School of Medicine, St. Louis, St. Louis, MO 63110, USA; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, St. Louis, MO 63110, USA.
Gilchuk P; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Yu J; Department of Genetics, Washington University School of Medicine, St. Louis, St. Louis, MO 63110, USA.
Bailey AL; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, St. Louis, MO 63110, USA.
Chen RE; Department of Medicine, Washington University School of Medicine, St. Louis, St. Louis, MO 63110, USA; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, St. Louis, MO 63110, USA.
Chong Z; Department of Medicine, Washington University School of Medicine, St. Louis, St. Louis, MO 63110, USA.
Zost SJ; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Jang H; Center for Vaccines and Immunology, University of Georgia, Athens, GA 30605, USA.
Huang Y; Center for Vaccines and Immunology, University of Georgia, Athens, GA 30605, USA.
Allen JD; Center for Vaccines and Immunology, University of Georgia, Athens, GA 30605, USA.
Case JB; Department of Medicine, Washington University School of Medicine, St. Louis, St. Louis, MO 63110, USA.
Sutton RE; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Carnahan RH; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Darling TL; Department of Medicine, Washington University School of Medicine, St. Louis, St. Louis, MO 63110, USA.
Boon ACM; Department of Medicine, Washington University School of Medicine, St. Louis, St. Louis, MO 63110, USA; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, St. Louis, MO 63110, USA; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, St. Louis, MO 63110, USA.
Mack M; Department of Internal Medicine II, University Hospital Regensburg, 93053 Regensburg, Germany.
Head RD; Department of Genetics, Washington University School of Medicine, St. Louis, St. Louis, MO 63110, USA.
Ross TM; Center for Vaccines and Immunology, University of Georgia, Athens, GA 30605, USA.
Crowe JE Jr; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address: .
Diamond MS; Department of Medicine, Washington University School of Medicine, St. Louis, St. Louis, MO 63110, USA; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, St. Louis, MO 63110, USA; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, St. Louis, MO 63110, USA; The Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, St. Louis, MO 63110, USA. Electronic address: .
Pokaż więcej
Źródło :
Cell [Cell] 2021 Apr 01; Vol. 184 (7), pp. 1804-1820.e16. Date of Electronic Publication: 2021 Feb 12.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal*/immunology
Antibodies, Monoclonal*/therapeutic use
Antibodies, Neutralizing*/immunology
Antibodies, Neutralizing*/therapeutic use
Antibodies, Viral*/immunology
Antibodies, Viral*/therapeutic use
CD8-Positive T-Lymphocytes*/cytology
CD8-Positive T-Lymphocytes*/immunology
COVID-19*/immunology
COVID-19*/therapy
Immunoglobulin Fc Fragments/*immunology
Animals ; CHO Cells ; Chlorocebus aethiops ; Cricetulus ; Disease Models, Animal ; Female ; Humans ; Male ; Mice ; Mice, Inbred C57BL ; SARS-CoV-2/immunology ; Vero Cells ; Viral Load
Czasopismo naukowe
Tytuł :
The development of neutralizing antibodies against SARS-CoV-2 and their common features.
Autorzy :
Liu LD; State Key Laboratory of Molecular Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences; University of Chinese Academy of Sciences, Shanghai 200031, China.
Lian C; Shanghai Institute of Immunology, State Key Laboratory of Oncogenes and Related Genes, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Yeap LS; Shanghai Institute of Immunology, State Key Laboratory of Oncogenes and Related Genes, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Meng FL; State Key Laboratory of Molecular Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences; University of Chinese Academy of Sciences, Shanghai 200031, China.
Pokaż więcej
Źródło :
Journal of molecular cell biology [J Mol Cell Biol] 2021 Mar 10; Vol. 12 (12), pp. 980-986.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antibodies, Neutralizing/*therapeutic use
Antibodies, Viral/*therapeutic use
COVID-19/*immunology
COVID-19/*therapy
SARS-CoV-2/*immunology
Animals ; Antibodies, Monoclonal, Humanized/immunology ; Antibodies, Monoclonal, Humanized/isolation & purification ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Monoclonal, Murine-Derived/immunology ; Antibodies, Monoclonal, Murine-Derived/isolation & purification ; Antibodies, Monoclonal, Murine-Derived/therapeutic use ; Antibodies, Neutralizing/immunology ; Antibodies, Neutralizing/isolation & purification ; Antibodies, Viral/immunology ; Antibodies, Viral/isolation & purification ; Antibody Diversity ; COVID-19/virology ; Drug Discovery ; Epitopes/chemistry ; Epitopes/immunology ; Humans ; Mice ; Models, Molecular ; Pandemics ; Spike Glycoprotein, Coronavirus/chemistry ; Spike Glycoprotein, Coronavirus/immunology
Czasopismo naukowe
Tytuł :
A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2.
Autorzy :
Yao H; CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China.; University of Chinese Academy of Sciences, Beijing, China.
Cai H; CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China.; University of Chinese Academy of Sciences, Beijing, China.
Li T; CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China.; University of Chinese Academy of Sciences, Beijing, China.
Zhou B; University of Chinese Academy of Sciences, Beijing, China.; CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.
Qin W; National Facility for Protein Science in Shanghai, Shanghai Advanced Research Institute (Zhangjiang Laboratory), Chinese Academy of Sciences, Shanghai, China.
Lavillette D; University of Chinese Academy of Sciences, Beijing, China.; CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.; Pasteurien College, Soochow University, Jiangsu, China.
Li D; CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China.; University of Chinese Academy of Sciences, Beijing, China.
Pokaż więcej
Źródło :
PLoS pathogens [PLoS Pathog] 2021 Mar 03; Vol. 17 (3), pp. e1009328. Date of Electronic Publication: 2021 Mar 03 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Angiotensin-Converting Enzyme 2/*immunology
Antibodies, Neutralizing/*immunology
Antibodies, Viral/*immunology
SARS-CoV-2/*immunology
Single-Domain Antibodies/*immunology
Antibodies, Neutralizing/chemistry ; Antibodies, Neutralizing/genetics ; Antibodies, Viral/chemistry ; Antibodies, Viral/genetics ; Antibody Affinity ; Binding Sites ; Crystallography, X-Ray ; HEK293 Cells ; Humans ; Models, Molecular ; Recombinant Fusion Proteins/chemistry ; Recombinant Fusion Proteins/genetics ; Recombinant Fusion Proteins/immunology ; Single-Domain Antibodies/chemistry ; Single-Domain Antibodies/genetics
Czasopismo naukowe
Tytuł :
Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo.
Autorzy :
Schäfer A; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Muecksch F; Laboratory of Retrovirology, The Rockefeller University, New York, NY.
Lorenzi JCC; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY.
Leist SR; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Cipolla M; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY.
Bournazos S; Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY.
Schmidt F; Laboratory of Retrovirology, The Rockefeller University, New York, NY.
Maison RM; Laboratory of Animal Reproduction and Biotechnology, Colorado State University, Fort Collins, CO.
Gazumyan A; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY.
Martinez DR; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Baric RS; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC.; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Robbiani DF; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY.; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
Hatziioannou T; Laboratory of Retrovirology, The Rockefeller University, New York, NY.
Ravetch JV; Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY.
Bieniasz PD; Laboratory of Retrovirology, The Rockefeller University, New York, NY.; Howard Hughes Medical Institute, The Rockefeller University, New York, NY.
Bowen RA; Laboratory of Animal Reproduction and Biotechnology, Colorado State University, Fort Collins, CO.
Nussenzweig MC; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY.; Howard Hughes Medical Institute, The Rockefeller University, New York, NY.
Sheahan TP; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Pokaż więcej
Źródło :
The Journal of experimental medicine [J Exp Med] 2021 Mar 01; Vol. 218 (3).
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Antibodies, Monoclonal, Murine-Derived*/immunology
Antibodies, Monoclonal, Murine-Derived*/pharmacology
Antibodies, Neutralizing*/immunology
Antibodies, Neutralizing*/pharmacology
Antibodies, Viral*/immunology
Antibodies, Viral*/pharmacology
Coronavirus Infections*/immunology
Coronavirus Infections*/therapy
Pandemics*
Pneumonia, Viral*/immunology
Pneumonia, Viral*/therapy
Betacoronavirus/*immunology
Animals ; COVID-19 ; Cell Line ; Female ; Humans ; Mesocricetus ; Mice ; Mice, Inbred BALB C ; SARS-CoV-2
Czasopismo naukowe
Tytuł :
Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC.
Autorzy :
Yoon HA; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
Bartash R; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
Gendlina I; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
Rivera J; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.; Department of Microbiology and Immunology and.
Nakouzi A; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.; Department of Microbiology and Immunology and.
Bortz RH 3rd; Department of Microbiology and Immunology and.
Wirchnianski AS; Department of Microbiology and Immunology and.; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
Paroder M; Department of Pathology and.
Fehn K; Department of Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
Serrano-Rahman L; Department of Pathology and.
Babb R; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.; Department of Microbiology and Immunology and.
Sarwar UN; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
Haslwanter D; Department of Microbiology and Immunology and.
Laudermilch E; Department of Microbiology and Immunology and.
Florez C; Department of Microbiology and Immunology and.; Department of Chemistry and Life Science, United States Military Academy at West Point, West Point, New York, USA.
Dieterle ME; Department of Microbiology and Immunology and.
Jangra RK; Department of Microbiology and Immunology and.
Fels JM; Department of Microbiology and Immunology and.
Tong K; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
Mariano MC; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
Vergnolle O; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
Georgiev GI; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
Herrera NG; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
Malonis RJ; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
Quiroz JA; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
Morano NC; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
Krause GJ; Department of Developmental & Molecular Biology.; Institute for Aging Research, and.
Sweeney JM; Department of Physiology and Biophysics, Albert Einstein College of Medicine, Bronx, New York, USA.
Cowman K; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
Allen S; Albert Einstein College of Medicine, Bronx, New York, USA.
Annam J; Albert Einstein College of Medicine, Bronx, New York, USA.
Applebaum A; Albert Einstein College of Medicine, Bronx, New York, USA.
Barboto D; Albert Einstein College of Medicine, Bronx, New York, USA.
Khokhar A; Albert Einstein College of Medicine, Bronx, New York, USA.
Lally BJ; Albert Einstein College of Medicine, Bronx, New York, USA.
Lee A; Albert Einstein College of Medicine, Bronx, New York, USA.
Lee M; Albert Einstein College of Medicine, Bronx, New York, USA.
Malaviya A; Albert Einstein College of Medicine, Bronx, New York, USA.
Sample R; Albert Einstein College of Medicine, Bronx, New York, USA.
Yang XA; Albert Einstein College of Medicine, Bronx, New York, USA.
Li Y; Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, USA.
Ruiz R; Network Performance Group, Montefiore Medical Center, Bronx, New York, USA.; Division of Hospital Medicine, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
Thota R; Network Performance Group, Montefiore Medical Center, Bronx, New York, USA.
Barnhill J; Department of Chemistry and Life Science, United States Military Academy at West Point, West Point, New York, USA.
Goldstein DY; Department of Pathology and.
Uehlinger J; Department of Pathology and.
Garforth SJ; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
Almo SC; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.; Department of Physiology and Biophysics, Albert Einstein College of Medicine, Bronx, New York, USA.
Lai JR; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
Gil MR; Department of Pathology and.
Fox AS; Department of Pathology and.
Chandran K; Department of Microbiology and Immunology and.
Wang T; Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, USA.
Daily JP; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.; Department of Microbiology and Immunology and.
Pirofski LA; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.; Department of Microbiology and Immunology and.
Pokaż więcej
Źródło :
JCI insight [JCI Insight] 2021 Feb 22; Vol. 6 (4). Date of Electronic Publication: 2021 Feb 22.
Typ publikacji :
Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Neutralizing/*administration & dosage
Antibodies, Viral/*administration & dosage
COVID-19/*therapy
SARS-CoV-2/*immunology
Adult ; Age Factors ; Aged ; Aged, 80 and over ; Antibodies, Neutralizing/blood ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/blood ; Antibodies, Viral/immunology ; COVID-19/immunology ; COVID-19/mortality ; COVID-19/virology ; Female ; Hospital Mortality ; Humans ; Immunization, Passive/methods ; Male ; Middle Aged ; New York City/epidemiology ; Propensity Score ; Retrospective Studies ; Spike Glycoprotein, Coronavirus/immunology ; Treatment Outcome
SCR Protocol :
COVID-19 serotherapy
Czasopismo naukowe
Tytuł :
Effective virus-neutralizing activities in antisera from the first wave of survivors of severe COVID-19.
Autorzy :
Han Y; Joint Laboratory of Infectious Diseases and Health, Wuhan Institute of Virology & Wuhan Jinyintan Hospital, Wuhan Jinyintan Hospital, Wuhan, Hubei, China.
Liu P; NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Qiu Y; Joint Laboratory of Infectious Diseases and Health, Wuhan Institute of Virology & Wuhan Jinyintan Hospital, Wuhan Jinyintan Hospital, Wuhan, Hubei, China.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China.
Zhou J; Joint Laboratory of Infectious Diseases and Health, Wuhan Institute of Virology & Wuhan Jinyintan Hospital, Wuhan Jinyintan Hospital, Wuhan, Hubei, China.
Liu Y; Joint Laboratory of Infectious Diseases and Health, Wuhan Institute of Virology & Wuhan Jinyintan Hospital, Wuhan Jinyintan Hospital, Wuhan, Hubei, China.
Hu X; Joint Laboratory of Infectious Diseases and Health, Wuhan Institute of Virology & Wuhan Jinyintan Hospital, Wuhan Jinyintan Hospital, Wuhan, Hubei, China.
Yang Q; Joint Laboratory of Infectious Diseases and Health, Wuhan Institute of Virology & Wuhan Jinyintan Hospital, Wuhan Jinyintan Hospital, Wuhan, Hubei, China.
Huang R; State Key Laboratory of Virology, Institute of Medical Virology and School of Basic Medical Sciences, Wuhan University, Wuhan, China.
Wen X; State Key Laboratory of Virology, Institute of Medical Virology and School of Basic Medical Sciences, Wuhan University, Wuhan, China.
Song H; Research Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, China.
Yu P; NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Yang M; NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Zhang J; NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Liu WJ; NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Peng K; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China.
Wu G; NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Zhang D; Joint Laboratory of Infectious Diseases and Health, Wuhan Institute of Virology & Wuhan Jinyintan Hospital, Wuhan Jinyintan Hospital, Wuhan, Hubei, China.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China.
Zhou X; Joint Laboratory of Infectious Diseases and Health, Wuhan Institute of Virology & Wuhan Jinyintan Hospital, Wuhan Jinyintan Hospital, Wuhan, Hubei, China.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China.
Wu Y; State Key Laboratory of Virology, Institute of Medical Virology and School of Basic Medical Sciences, Wuhan University, Wuhan, China.
Pokaż więcej
Źródło :
JCI insight [JCI Insight] 2021 Feb 22; Vol. 6 (4). Date of Electronic Publication: 2021 Feb 22.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Neutralizing/*immunology
Antibodies, Viral/*immunology
COVID-19/*immunology
Immunoglobulin G/*immunology
SARS-CoV-2/*immunology
Adult ; Aged ; Antibodies, Neutralizing/blood ; Antibodies, Neutralizing/isolation & purification ; Antibodies, Viral/blood ; Antibodies, Viral/isolation & purification ; COVID-19/blood ; COVID-19/diagnosis ; COVID-19/virology ; China ; Cohort Studies ; Female ; Humans ; Immune Sera ; Immunity, Humoral ; Immunoglobulin G/blood ; Immunoglobulin G/isolation & purification ; Male ; Middle Aged ; Survivors ; Time Factors
Czasopismo naukowe
Tytuł :
Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape.
Autorzy :
Koenig PA; Core Facility Nanobodies, Medical Faculty, University of Bonn, 53127 Bonn, Germany. .; Institute of Innate Immunity, Medical Faculty, University of Bonn, 53127 Bonn, Germany.
Das H; Department of Cell and Molecular Biology, Karolinska Institutet, 17177 Stockholm, Sweden.
Liu H; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Kümmerer BM; Institute of Virology, Medical Faculty, University of Bonn, 53127 Bonn, Germany.; German Centre for Infection Research (DZIF), partner site Bonn-Cologne, 53127 Bonn, Germany.
Gohr FN; Institute of Innate Immunity, Medical Faculty, University of Bonn, 53127 Bonn, Germany.
Jenster LM; Institute of Innate Immunity, Medical Faculty, University of Bonn, 53127 Bonn, Germany.
Schiffelers LDJ; Institute of Innate Immunity, Medical Faculty, University of Bonn, 53127 Bonn, Germany.
Tesfamariam YM; Institute of Innate Immunity, Medical Faculty, University of Bonn, 53127 Bonn, Germany.
Uchima M; Institute of Innate Immunity, Medical Faculty, University of Bonn, 53127 Bonn, Germany.
Wuerth JD; Institute of Innate Immunity, Medical Faculty, University of Bonn, 53127 Bonn, Germany.
Gatterdam K; Institute of Structural Biology, Medical Faculty, University of Bonn, 53127 Bonn, Germany.
Ruetalo N; Institute for Medical Virology and Epidemiology, Section Molecular Virology, University Hospital Tübingen, 72076 Tübingen, Germany.
Christensen MH; Institute of Innate Immunity, Medical Faculty, University of Bonn, 53127 Bonn, Germany.
Fandrey CI; Institute of Innate Immunity, Medical Faculty, University of Bonn, 53127 Bonn, Germany.
Normann S; Institute of Innate Immunity, Medical Faculty, University of Bonn, 53127 Bonn, Germany.
Tödtmann JMP; Core Facility Nanobodies, Medical Faculty, University of Bonn, 53127 Bonn, Germany.
Pritzl S; Core Facility Nanobodies, Medical Faculty, University of Bonn, 53127 Bonn, Germany.
Hanke L; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 17177 Stockholm, Sweden.
Boos J; Institute of Human Genetics, Medical Faculty, University of Bonn, 53127 Bonn, Germany.
Yuan M; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Zhu X; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Schmid-Burgk JL; Institute for Clinical Chemistry and Clinical Pharmacology, Medical Faculty, University of Bonn, 53127 Bonn, Germany.
Kato H; Institute of Cardiovascular Immunology, Medical Faculty, University of Bonn, 53127 Bonn, Germany.
Schindler M; Institute for Medical Virology and Epidemiology, Section Molecular Virology, University Hospital Tübingen, 72076 Tübingen, Germany.
Wilson IA; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.; The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Geyer M; Institute of Structural Biology, Medical Faculty, University of Bonn, 53127 Bonn, Germany.
Ludwig KU; Institute of Human Genetics, Medical Faculty, University of Bonn, 53127 Bonn, Germany.
Hällberg BM; Department of Cell and Molecular Biology, Karolinska Institutet, 17177 Stockholm, Sweden. .; Centre for Structural Systems Biology (CSSB) and Karolinska Institutet VR-RÅC, Notkestrasse 85, 22607 Hamburg, Germany.
Wu NC; Department of Biochemistry, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA. .; Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.; Center for Biophysics and Quantitative Biology, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
Schmidt FI; Core Facility Nanobodies, Medical Faculty, University of Bonn, 53127 Bonn, Germany. .; Institute of Innate Immunity, Medical Faculty, University of Bonn, 53127 Bonn, Germany.
Pokaż więcej
Źródło :
Science (New York, N.Y.) [Science] 2021 Feb 12; Vol. 371 (6530). Date of Electronic Publication: 2021 Jan 12.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Neutralizing/*immunology
Antibodies, Viral/*immunology
COVID-19/*immunology
SARS-CoV-2/*immunology
Single-Domain Antibodies/*immunology
Spike Glycoprotein, Coronavirus/*immunology
Amino Acid Substitution ; Angiotensin-Converting Enzyme 2/metabolism ; Animals ; Antibodies, Neutralizing/chemistry ; Antibodies, Neutralizing/metabolism ; Antibodies, Viral/chemistry ; Antibodies, Viral/metabolism ; Antibody Affinity ; Antigens, Viral/immunology ; Binding Sites, Antibody ; COVID-19/virology ; Cell Line ; Cryoelectron Microscopy ; Epitopes ; Humans ; Membrane Fusion ; Mutation ; Protein Binding ; Protein Conformation ; Protein Domains ; Receptors, Coronavirus/metabolism ; SARS-CoV-2/genetics ; SARS-CoV-2/physiology ; Single-Domain Antibodies/chemistry ; Single-Domain Antibodies/metabolism ; Spike Glycoprotein, Coronavirus/chemistry ; Spike Glycoprotein, Coronavirus/genetics ; Spike Glycoprotein, Coronavirus/metabolism ; Virus Replication
Czasopismo naukowe
Tytuł :
Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody.
Autorzy :
Rosenfeld R; Israel Institute for Biological Research, Ness-Ziona, Israel. .
Noy-Porat T; Israel Institute for Biological Research, Ness-Ziona, Israel.
Mechaly A; Israel Institute for Biological Research, Ness-Ziona, Israel.
Makdasi E; Israel Institute for Biological Research, Ness-Ziona, Israel.
Levy Y; Israel Institute for Biological Research, Ness-Ziona, Israel.
Alcalay R; Israel Institute for Biological Research, Ness-Ziona, Israel.
Falach R; Israel Institute for Biological Research, Ness-Ziona, Israel.
Aftalion M; Israel Institute for Biological Research, Ness-Ziona, Israel.
Epstein E; Israel Institute for Biological Research, Ness-Ziona, Israel.
Gur D; Israel Institute for Biological Research, Ness-Ziona, Israel.
Chitlaru T; Israel Institute for Biological Research, Ness-Ziona, Israel.
Vitner EB; Israel Institute for Biological Research, Ness-Ziona, Israel.
Melamed S; Israel Institute for Biological Research, Ness-Ziona, Israel.
Politi B; Israel Institute for Biological Research, Ness-Ziona, Israel.
Zauberman A; Israel Institute for Biological Research, Ness-Ziona, Israel.
Lazar S; Israel Institute for Biological Research, Ness-Ziona, Israel.
Beth-Din A; Israel Institute for Biological Research, Ness-Ziona, Israel.
Evgy Y; Israel Institute for Biological Research, Ness-Ziona, Israel.
Yitzhaki S; Israel Institute for Biological Research, Ness-Ziona, Israel.
Shapira SC; Israel Institute for Biological Research, Ness-Ziona, Israel.
Israely T; Israel Institute for Biological Research, Ness-Ziona, Israel.
Mazor O; Israel Institute for Biological Research, Ness-Ziona, Israel. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2021 Feb 11; Vol. 12 (1), pp. 944. Date of Electronic Publication: 2021 Feb 11.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal/*administration & dosage
Antibodies, Neutralizing/*administration & dosage
Antibodies, Viral/*administration & dosage
COVID-19/*immunology
Animals ; Antibodies, Monoclonal/genetics ; Antibodies, Monoclonal/immunology ; Antibodies, Neutralizing/genetics ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/genetics ; Antibodies, Viral/immunology ; COVID-19/drug therapy ; Chlorocebus aethiops ; Female ; Immunoglobulin G/administration & dosage ; Immunoglobulin G/genetics ; Immunoglobulin G/immunology ; Lung/pathology ; Lung/virology ; Male ; Mice, Inbred C57BL ; Mice, Transgenic ; SARS-CoV-2/classification ; SARS-CoV-2/physiology ; Seroconversion ; Vero Cells ; Viral Load
Czasopismo naukowe
Tytuł :
Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors.
Autorzy :
Mor M; Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.
Werbner M; Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Alter J; Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Safra M; Alexander Kofkin Faculty of Engineering, Bar Ilan University, Ramat Gan, Israel.
Chomsky E; ImmunAi, New York, New York, United States of America.
Lee JC; School of Medicine, University of California San Diego, La Jolla, California, United States of America.
Hada-Neeman S; George S. Wise Life sciences Faculty, Tel Aviv University, Tel-Aviv, Israel.
Polonsky K; Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.
Nowell CJ; Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.
Clark AE; School of Medicine, University of California San Diego, La Jolla, California, United States of America.
Roitburd-Berman A; George S. Wise Life sciences Faculty, Tel Aviv University, Tel-Aviv, Israel.
Ben-Shalom N; Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.
Navon M; Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.
Rafael D; Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.
Sharim H; ImmunAi, New York, New York, United States of America.
Kiner E; ImmunAi, New York, New York, United States of America.
Griffis ER; Nikon Imaging Center, University of California San Diego, California, United States of America.
Gershoni JM; George S. Wise Life sciences Faculty, Tel Aviv University, Tel-Aviv, Israel.
Kobiler O; Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.
Leibel SL; School of Medicine, University of California San Diego, La Jolla, California, United States of America.
Zimhony O; Kaplan Medical Center, Rehovot, Israel.
Carlin AF; School of Medicine, University of California San Diego, La Jolla, California, United States of America.
Yaari G; Alexander Kofkin Faculty of Engineering, Bar Ilan University, Ramat Gan, Israel.
Dessau M; Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Gal-Tanamy M; Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Hagin D; Ichilov Hospital, Tel-Aviv, Israel.
Croker BA; School of Medicine, University of California San Diego, La Jolla, California, United States of America.
Freund NT; Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.
Pokaż więcej
Źródło :
PLoS pathogens [PLoS Pathog] 2021 Feb 11; Vol. 17 (2), pp. e1009165. Date of Electronic Publication: 2021 Feb 11 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal*/genetics
Antibodies, Monoclonal*/immunology
Antibodies, Neutralizing*/genetics
Antibodies, Neutralizing*/immunology
Antibodies, Viral*/genetics
Antibodies, Viral*/immunology
COVID-19*/genetics
COVID-19*/immunology
Convalescence*
SARS-CoV-2*/immunology
Spike Glycoprotein, Coronavirus*/genetics
Spike Glycoprotein, Coronavirus*/immunology
Adult ; Aged ; Animals ; Chlorocebus aethiops ; Cloning, Molecular ; Epitope Mapping ; Epitopes/genetics ; Epitopes/immunology ; Female ; Humans ; Immunoglobulin G/genetics ; Immunoglobulin G/immunology ; Male ; Middle Aged ; Vero Cells
Czasopismo naukowe
Tytuł :
Longitudinal SARS-CoV-2 seroconversion and functional heterogeneity in a pediatric dialysis unit.
Autorzy :
Canas JJ; Department of Pediatrics, Indiana University, Indianapolis, Indiana, USA; Department of Microbiology and Immunology, Indiana University, Indianapolis, Indiana, USA.
Starr MC; Department of Pediatrics, Indiana University, Indianapolis, Indiana, USA.
Hooks J; Department of Pediatrics, Indiana University, Indianapolis, Indiana, USA.
Arregui S; Department of Pediatrics, Indiana University, Indianapolis, Indiana, USA.
Wilson AC; Department of Pediatrics, Indiana University, Indianapolis, Indiana, USA.
Carroll AE; Department of Pediatrics, Indiana University, Indianapolis, Indiana, USA.
Saxena V; Department of Pediatrics, Indiana University, Indianapolis, Indiana, USA.
Amanat F; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Krammer F; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Fill J; Clinical Diagnostics Laboratory, Eli Lilly and Company, Indianapolis, Indiana, USA.
Schade A; Clinical Diagnostics Laboratory, Eli Lilly and Company, Indianapolis, Indiana, USA.
Chambers A; Clinical Diagnostics Laboratory, Eli Lilly and Company, Indianapolis, Indiana, USA.
Schneider J; Department of Pediatrics, Indiana University, Indianapolis, Indiana, USA.
Schwaderer AL; Department of Pediatrics, Indiana University, Indianapolis, Indiana, USA. Electronic address: .
Hains DS; Department of Pediatrics, Indiana University, Indianapolis, Indiana, USA; Department of Microbiology and Immunology, Indiana University, Indianapolis, Indiana, USA. Electronic address: .
Pokaż więcej
Źródło :
Kidney international [Kidney Int] 2021 Feb; Vol. 99 (2), pp. 484-486.
Typ publikacji :
Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Seroconversion*
Antibodies, Neutralizing/*blood
Antibodies, Viral/*blood
COVID-19/*immunology
Renal Dialysis/*adverse effects
SARS-CoV-2/*immunology
Antibodies, Neutralizing/immunology ; Antibodies, Neutralizing/isolation & purification ; Antibodies, Viral/immunology ; Antibodies, Viral/isolation & purification ; Asymptomatic Infections/epidemiology ; COVID-19/diagnosis ; COVID-19/epidemiology ; COVID-19/transmission ; COVID-19 Nucleic Acid Testing/statistics & numerical data ; COVID-19 Serological Testing/statistics & numerical data ; Child ; Female ; Hospitals, Pediatric/statistics & numerical data ; Humans ; Infectious Disease Transmission, Patient-to-Professional/statistics & numerical data ; Longitudinal Studies ; SARS-CoV-2/genetics ; SARS-CoV-2/isolation & purification ; Viral Load/immunology
Raport
Tytuł :
Decline and loss of anti-SARS-CoV-2 antibodies in kidney transplant recipients in the 6 months following SARS-CoV-2 infection.
Autorzy :
Chavarot N; Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France. Electronic address: .
Leruez-Ville M; Université de Paris, Paris, France; Department of Virology, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Scemla A; Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France.
Burger C; Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France.
Amrouche L; Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France.
Rouzaud C; Université de Paris, Paris, France; Department of Infectious Diseases and Tropical Medicine, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Lebreton X; Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Martinez F; Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France.
Sberro-Soussan R; Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France.
Legendre C; Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France.
Zuber J; Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France.
Anglicheau D; Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France.
Pokaż więcej
Źródło :
Kidney international [Kidney Int] 2021 Feb; Vol. 99 (2), pp. 486-488.
Typ publikacji :
Letter
MeSH Terms :
Antibodies, Neutralizing/*blood
Antibodies, Viral/*blood
COVID-19/*immunology
Kidney Transplantation/*adverse effects
SARS-CoV-2/*immunology
Transplant Recipients/*statistics & numerical data
Aged ; Antibodies, Neutralizing/immunology ; Antibodies, Neutralizing/isolation & purification ; Antibodies, Viral/immunology ; Antibodies, Viral/isolation & purification ; COVID-19/blood ; COVID-19/diagnosis ; COVID-19/virology ; COVID-19 Nucleic Acid Testing ; COVID-19 Serological Testing/statistics & numerical data ; Female ; Humans ; Immunocompromised Host/immunology ; Immunoglobulin G/blood ; Immunoglobulin G/immunology ; Immunoglobulin G/isolation & purification ; Male ; Middle Aged ; SARS-CoV-2/genetics ; SARS-CoV-2/isolation & purification ; Severity of Illness Index ; Time Factors
Opinia redakcyjna
Tytuł :
Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates.
Autorzy :
Boonyaratanakornkit J; Department of Medicine, University of Washington, Seattle, Washington, USA.; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.; Seattle Cancer Care Alliance, Seattle, Washington, USA.
Morishima C; Department of Laboratory Medicine and Pathology, and.
Selke S; Department of Laboratory Medicine and Pathology, and.
Zamora D; Department of Medicine, University of Washington, Seattle, Washington, USA.; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
McGuffin S; Department of Medicine, University of Washington, Seattle, Washington, USA.
Shapiro AE; Department of Medicine, University of Washington, Seattle, Washington, USA.; Department of Global Health, University of Washington, Seattle, Washington, USA.
Campbell VL; Department of Medicine, University of Washington, Seattle, Washington, USA.
McClurkan CL; Department of Medicine, University of Washington, Seattle, Washington, USA.
Jing L; Department of Medicine, University of Washington, Seattle, Washington, USA.
Gross R; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Frederick, Maryland, USA.
Liang J; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Frederick, Maryland, USA.
Postnikova E; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Frederick, Maryland, USA.
Mazur S; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Frederick, Maryland, USA.
Lukin VV; Kearney, Chicago, Illinois, USA.
Chaudhary A; Department of Laboratory Medicine and Pathology, and.
Das MK; Department of Laboratory Medicine and Pathology, and.
Fink SL; Department of Laboratory Medicine and Pathology, and.
Bryan A; Department of Laboratory Medicine and Pathology, and.
Greninger AL; Department of Laboratory Medicine and Pathology, and.
Jerome KR; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.; Department of Laboratory Medicine and Pathology, and.
Holbrook MR; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Frederick, Maryland, USA.
Gernsheimer TB; Department of Medicine, University of Washington, Seattle, Washington, USA.; Seattle Cancer Care Alliance, Seattle, Washington, USA.
Wener MH; Department of Medicine, University of Washington, Seattle, Washington, USA.; Department of Laboratory Medicine and Pathology, and.
Wald A; Department of Medicine, University of Washington, Seattle, Washington, USA.; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.; Department of Epidemiology, University of Washington, Seattle, Washington, USA.
Koelle DM; Department of Medicine, University of Washington, Seattle, Washington, USA.; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.; Department of Laboratory Medicine and Pathology, and.; Department of Global Health, University of Washington, Seattle, Washington, USA.; Benaroya Research Institute, Seattle, Washington, USA.
Pokaż więcej
Źródło :
The Journal of clinical investigation [J Clin Invest] 2021 Feb 01; Vol. 131 (3).
Typ publikacji :
Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Antibodies, Neutralizing*/blood
Antibodies, Neutralizing*/immunology
Antibodies, Viral*/blood
Antibodies, Viral*/immunology
Blood Donors*
Immunoglobulin G*/blood
Immunoglobulin G*/immunology
SARS-CoV-2*/immunology
SARS-CoV-2*/metabolism
COVID-19/*therapy
Adult ; Aged ; Aged, 80 and over ; COVID-19/blood ; COVID-19/immunology ; Female ; Humans ; Immunization, Passive ; Male ; Middle Aged
SCR Protocol :
COVID-19 serotherapy
Czasopismo naukowe
Tytuł :
Extremely potent human monoclonal antibodies from COVID-19 convalescent patients.
Autorzy :
Andreano E; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.
Nicastri E; National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy.
Paciello I; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.
Pileri P; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.
Manganaro N; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.
Piccini G; VisMederi S.r.l, Siena, Italy.
Manenti A; VisMederi S.r.l, Siena, Italy; VisMederi Research S.r.l., Siena, Italy.
Pantano E; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.
Kabanova A; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy; Tumour Immunology Unit, Fondazione Toscana Life Sciences, Siena, Italy.
Troisi M; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy; Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.
Vacca F; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy; Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.
Cardamone D; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy; University of Turin, Turin, Italy.
De Santi C; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.
Torres JL; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Ozorowski G; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Benincasa L; VisMederi Research S.r.l., Siena, Italy.
Jang H; Center for Vaccines and Immunology, University of Georgia, Athens, GA 30602, USA.
Di Genova C; Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, Chatham, UK.
Depau L; MedBiotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Brunetti J; MedBiotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Agrati C; National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy.
Capobianchi MR; National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy.
Castilletti C; National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy.
Emiliozzi A; Department of Medical Biotechnologies, University of Siena, Siena, Italy; Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy.
Fabbiani M; Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy.
Montagnani F; Department of Medical Biotechnologies, University of Siena, Siena, Italy; Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy.
Bracci L; MedBiotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Sautto G; Center for Vaccines and Immunology, University of Georgia, Athens, GA 30602, USA.
Ross TM; Center for Vaccines and Immunology, University of Georgia, Athens, GA 30602, USA; Department of Infectious Diseases, University of Georgia, Athens, GA 30602, USA.
Montomoli E; VisMederi S.r.l, Siena, Italy; VisMederi Research S.r.l., Siena, Italy; Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.
Temperton N; Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, Chatham, UK.
Ward AB; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Sala C; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.
Ippolito G; National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy.
Rappuoli R; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy; Faculty of Medicine, Imperial College, London, UK. Electronic address: .
Pokaż więcej
Źródło :
Cell [Cell] 2021 Apr 01; Vol. 184 (7), pp. 1821-1835.e16. Date of Electronic Publication: 2021 Feb 23.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
COVID-19*/immunology
COVID-19*/prevention & control
COVID-19*/therapy
Convalescence*
Antibodies, Monoclonal/*administration & dosage
Antibodies, Neutralizing/*administration & dosage
Antibodies, Viral/*administration & dosage
B-Lymphocytes/*immunology
3T3 Cells ; Animals ; Antibodies, Monoclonal/isolation & purification ; Antibodies, Neutralizing/isolation & purification ; Antibodies, Viral/isolation & purification ; B-Lymphocytes/cytology ; Chlorocebus aethiops ; Disease Models, Animal ; Female ; HEK293 Cells ; Humans ; Immunoglobulin Fc Fragments/immunology ; Male ; Mice ; Spike Glycoprotein, Coronavirus/immunology ; Vero Cells
Czasopismo naukowe
Tytuł :
Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library.
Autorzy :
Bell BN; Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, California, USA.; Stanford ChEM-H, Stanford University, Stanford, California, USA.
Powell AE; Stanford ChEM-H, Stanford University, Stanford, California, USA.; Department of Biochemistry, Stanford University School of Medicine, Stanford, California, USA.
Rodriguez C; xCella Biosciences, Menlo Park, California, USA.
Cochran JR; Department of Bioengineering, Stanford University, Stanford, California, USA.; Department of Chemical Engineering, Stanford University, Stanford, California, USA.
Kim PS; Stanford ChEM-H, Stanford University, Stanford, California, USA.; Department of Biochemistry, Stanford University School of Medicine, Stanford, California, USA.; Chan Zuckerberg Biohub, San Francisco, California, USA.
Pokaż więcej
Źródło :
Protein science : a publication of the Protein Society [Protein Sci] 2021 Apr; Vol. 30 (4), pp. 716-727. Date of Electronic Publication: 2021 Feb 24.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Angiotensin-Converting Enzyme 2/*metabolism
Antibodies, Neutralizing/*metabolism
COVID-19/*metabolism
SARS-CoV-2/*physiology
Spike Glycoprotein, Coronavirus/*metabolism
Antibodies, Neutralizing/chemistry ; Binding Sites ; Epitopes/chemistry ; Epitopes/metabolism ; Humans ; Molecular Docking Simulation ; Protein Binding ; Protein Interaction Domains and Motifs ; Spike Glycoprotein, Coronavirus/chemistry
Czasopismo naukowe
Tytuł :
Suitability of two rapid lateral flow immunochromatographic assays for predicting SARS-CoV-2 neutralizing activity of sera.
Autorzy :
Valdivia A; Microbiology Service, Hospital Clínico Universitario, INCLIVA Health Research Institute, Valencia, Spain.
Torres I; Microbiology Service, Hospital Clínico Universitario, INCLIVA Health Research Institute, Valencia, Spain.
Latorre V; Institute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain.
Francés-Gómez C; Institute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain.
Ferrer J; Microbiology Service, Hospital Clínico Universitario, INCLIVA Health Research Institute, Valencia, Spain.
Forqué L; Microbiology Service, Hospital Clínico Universitario, INCLIVA Health Research Institute, Valencia, Spain.
Costa R; Microbiology Service, Hospital Clínico Universitario, INCLIVA Health Research Institute, Valencia, Spain.
de la Asunción CS; Microbiology Service, Hospital Clínico Universitario, INCLIVA Health Research Institute, Valencia, Spain.
Huntley D; Microbiology Service, Hospital Clínico Universitario, INCLIVA Health Research Institute, Valencia, Spain.
Gozalbo-Rovira R; School of Medicine, Department of Microbiology, University of Valencia, Valencia, Spain.
Buesa J; Microbiology Service, Hospital Clínico Universitario, INCLIVA Health Research Institute, Valencia, Spain.; School of Medicine, Department of Microbiology, University of Valencia, Valencia, Spain.
Giménez E; Microbiology Service, Hospital Clínico Universitario, INCLIVA Health Research Institute, Valencia, Spain.
Rodríguez-Díaz J; School of Medicine, Department of Microbiology, University of Valencia, Valencia, Spain.
Geller R; Institute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain.
Navarro D; Microbiology Service, Hospital Clínico Universitario, INCLIVA Health Research Institute, Valencia, Spain.; School of Medicine, Department of Microbiology, University of Valencia, Valencia, Spain.
Pokaż więcej
Źródło :
Journal of medical virology [J Med Virol] 2021 Apr; Vol. 93 (4), pp. 2301-2306. Date of Electronic Publication: 2020 Dec 17.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Neutralizing/*blood
COVID-19/*immunology
COVID-19 Testing/*methods
Immunoassay/*methods
SARS-CoV-2/*immunology
Antibodies, Neutralizing/immunology ; Antibodies, Viral/blood ; Antibodies, Viral/immunology ; COVID-19/blood ; COVID-19/diagnosis ; COVID-19/virology ; Green Fluorescent Proteins ; Humans ; Immunoglobulin G/blood ; Immunoglobulin M/blood ; Spike Glycoprotein, Coronavirus/immunology
Czasopismo naukowe
Tytuł :
Monoclonal Antibody for Patients with Covid-19.
Autorzy :
Jaworski JP; Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina .
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Mar 25; Vol. 384 (12), pp. 1170-1171. Date of Electronic Publication: 2021 Feb 03.
Typ publikacji :
Letter; Comment
MeSH Terms :
Antibodies, Neutralizing*
COVID-19*
Antibodies, Monoclonal ; Antibodies, Viral ; Humans ; SARS-CoV-2
Opinia redakcyjna
Tytuł :
Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma.
Autorzy :
Donato ML; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Park S; Hackensack Meridian Health Center for Discovery and Innovation, Nutley, New Jersey, USA.
Baker M; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Korngold R; Hackensack Meridian Health Center for Discovery and Innovation, Nutley, New Jersey, USA.
Morawski A; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Geng X; Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown University, Washington, DC, USA.
Tan M; Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown University, Washington, DC, USA.
Ip A; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Goldberg S; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Rowley S; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Chow K; Hackensack University Medical Center, Hackensack, New Jersey, USA.
Brown E; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Zenreich J; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
McKiernan P; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Buttner K; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Ullrich A; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Long L; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Feinman R; Hackensack Meridian Health Center for Discovery and Innovation, Nutley, New Jersey, USA.
Ricourt A; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Kemp M; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Vendivil M; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Suh H; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Balani B; Hackensack University Medical Center, Hackensack, New Jersey, USA.
Cicogna C; Hackensack University Medical Center, Hackensack, New Jersey, USA.
Sebti R; Hackensack University Medical Center, Hackensack, New Jersey, USA.
Al-Khan A; Hackensack University Medical Center, Hackensack, New Jersey, USA.
Sperber S; Hackensack University Medical Center, Hackensack, New Jersey, USA.
Desai S; Hackensack University Medical Center, Hackensack, New Jersey, USA.
Fanning S; Hackensack Meridian Health Center for Discovery and Innovation, Nutley, New Jersey, USA.
Arad D; Hackensack University Medical Center, Hackensack, New Jersey, USA.
Go R; Hackensack University Medical Center, Hackensack, New Jersey, USA.
Tam E; Hackensack University Medical Center, Hackensack, New Jersey, USA.
Rose K; Hackensack University Medical Center, Hackensack, New Jersey, USA.
Sadikot S; Hackensack University Medical Center, Hackensack, New Jersey, USA.
Siegel D; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Gutierrez M; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Feldman T; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Goy A; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Pecora A; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Biran N; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Leslie L; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Gillio A; Hackensack University Medical Center, Hackensack, New Jersey, USA.
Timmapuri S; Hackensack University Medical Center, Hackensack, New Jersey, USA.
Boonstra M; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Singer S; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Kaur S; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Richards E; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Perlin DS; Hackensack Meridian Health Center for Discovery and Innovation, Nutley, New Jersey, USA.
Pokaż więcej
Źródło :
JCI insight [JCI Insight] 2021 Mar 22; Vol. 6 (6). Date of Electronic Publication: 2021 Mar 22.
Typ publikacji :
Clinical Trial, Phase II; Journal Article
MeSH Terms :
Plasma*
Severity of Illness Index*
Antibodies, Neutralizing/*therapeutic use
Antibodies, Viral/*therapeutic use
COVID-19/*therapy
Immunoglobulin G/*therapeutic use
SARS-CoV-2/*immunology
Aged ; Antibodies, Neutralizing/blood ; Antibodies, Viral/blood ; COVID-19/immunology ; COVID-19/mortality ; COVID-19/virology ; Convalescence ; Female ; Humans ; Immunization, Passive ; Immunocompromised Host ; Immunoglobulin G/blood ; Male ; Middle Aged ; Pneumonia ; Respiration, Artificial
SCR Protocol :
COVID-19 serotherapy
Czasopismo naukowe
Tytuł :
Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study.
Autorzy :
He Z; Wuhan Center for Disease Control & Prevention, Wuhan, China.
Ren L; National Health Commission Key Laboratory of Systems Biology of Pathogens and Christophe Mérieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; Key Laboratory of Respiratory Disease Pathogenomics, Chinese Academy of Medical Sciences, Beijing, China.
Yang J; State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Guo L; National Health Commission Key Laboratory of Systems Biology of Pathogens and Christophe Mérieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; Key Laboratory of Respiratory Disease Pathogenomics, Chinese Academy of Medical Sciences, Beijing, China.
Feng L; School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Ma C; National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Wang X; Wuhan Center for Disease Control & Prevention, Wuhan, China.
Leng Z; School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Tong X; Department of Pulmonary and Critical Care Medicine, Beijing Hospital, National Center for Gerontology, Institute of Geriatric Medicine of Chinese Academy of Medical Sciences, Beijing, China.
Zhou W; Wuhan Center for Disease Control & Prevention, Wuhan, China.
Wang G; National Health Commission Key Laboratory of Systems Biology of Pathogens and Christophe Mérieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; Key Laboratory of Respiratory Disease Pathogenomics, Chinese Academy of Medical Sciences, Beijing, China.
Zhang T; School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Guo Y; Wuhan Center for Disease Control & Prevention, Wuhan, China.
Wu C; National Health Commission Key Laboratory of Systems Biology of Pathogens and Christophe Mérieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Wang Q; School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Liu M; Wuhan Center for Disease Control & Prevention, Wuhan, China.
Wang C; National Health Commission Key Laboratory of Systems Biology of Pathogens and Christophe Mérieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Jia M; School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Hu X; Wuhan Center for Disease Control & Prevention, Wuhan, China.
Wang Y; National Health Commission Key Laboratory of Systems Biology of Pathogens and Christophe Mérieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Zhang X; School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Hu R; Wuhan Center for Disease Control & Prevention, Wuhan, China.
Zhong J; National Health Commission Key Laboratory of Systems Biology of Pathogens and Christophe Mérieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Yang J; School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Dai J; Wuhan Center for Disease Control & Prevention, Wuhan, China.
Chen L; National Health Commission Key Laboratory of Systems Biology of Pathogens and Christophe Mérieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Zhou X; Wuhan Center for Disease Control & Prevention, Wuhan, China.
Wang J; National Health Commission Key Laboratory of Systems Biology of Pathogens and Christophe Mérieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; Key Laboratory of Respiratory Disease Pathogenomics, Chinese Academy of Medical Sciences, Beijing, China. Electronic address: .
Yang W; School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Electronic address: .
Wang C; School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China; National Center for Respiratory Medicine, Beijing, China; Chinese Academy of Engineering, Beijing, China. Electronic address: .
Pokaż więcej
Źródło :
Lancet (London, England) [Lancet] 2021 Mar 20; Vol. 397 (10279), pp. 1075-1084.
Typ publikacji :
Journal Article; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Neutralizing/*blood
Antibodies, Viral/*blood
COVID-19/*immunology
SARS-CoV-2/*immunology
Adolescent ; Adult ; Aged ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/immunology ; COVID-19/blood ; COVID-19/epidemiology ; COVID-19/prevention & control ; Child ; Child, Preschool ; China/epidemiology ; Coronavirus Nucleocapsid Proteins/immunology ; Cross-Sectional Studies ; Female ; Follow-Up Studies ; Humans ; Immunity, Herd/immunology ; Immunity, Humoral ; Infant ; Infant, Newborn ; Longitudinal Studies ; Male ; Mass Vaccination/organization & administration ; Middle Aged ; Seroepidemiologic Studies ; Young Adult
Czasopismo naukowe
Tytuł :
Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China.
Autorzy :
Feng X; Beijing Youan Hospital, Capital Medical University, Beijing, China.
Yin J; Beijing Youan Hospital, Capital Medical University, Beijing, China.; Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Zhang J; Beijing Youan Hospital, Capital Medical University, Beijing, China.
Hu Y; Sinovac Biotech Ltd., Beijing, China.
Ouyang Y; Beijing Youan Hospital, Capital Medical University, Beijing, China.; Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Qiao S; Beijing Fengtai Hospital of Integrated Traditional and Western Medicine, Beijing, China.
Zhao H; Department of Infectious Diseases, Peking University First Hospital, Beijing, China.
Zhang T; Beijing Youan Hospital, Capital Medical University, Beijing, China.
Li X; Beijing Youan Hospital, Capital Medical University, Beijing, China.
Zhang L; Beijing Youan Hospital, Capital Medical University, Beijing, China.
Zhang J; Beijing Key Laboratory of Monoclonal Antibody Research and Development, Sino Biological Inc., Beijing, China.
Jin R; Beijing Youan Hospital, Capital Medical University, Beijing, China.
Feng Y; Beijing Youan Hospital, Capital Medical University, Beijing, China.
Su B; Beijing Youan Hospital, Capital Medical University, Beijing, China.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2021 Mar 15; Vol. 12, pp. 614436. Date of Electronic Publication: 2021 Mar 15 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Neutralizing/*blood
Antibodies, Viral/*blood
COVID-19/*immunology
Coronavirus Nucleocapsid Proteins/*immunology
SARS-CoV-2/*immunology
Spike Glycoprotein, Coronavirus/*immunology
Adult ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/immunology ; Beijing ; COVID-19/pathology ; China ; Female ; Humans ; Immunoglobulin G/blood ; Immunoglobulin M/blood ; Male ; Middle Aged ; Phosphoproteins/immunology ; Protein Domains/immunology ; Seroconversion ; Severity of Illness Index ; Tertiary Care Centers
Czasopismo naukowe
Tytuł :
SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.
Autorzy :
Bertoglio F; Technische Universität Braunschweig, Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie, Braunschweig, Germany.
Meier D; Technische Universität Braunschweig, Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie, Braunschweig, Germany.
Langreder N; Technische Universität Braunschweig, Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie, Braunschweig, Germany.
Steinke S; Technische Universität Braunschweig, Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie, Braunschweig, Germany.
Rand U; Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Simonelli L; Institute for Research in Biomedicine (IRB), Università della Svizzera italiana (USI), Bellinzona, Switzerland.
Heine PA; Technische Universität Braunschweig, Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie, Braunschweig, Germany.
Ballmann R; Technische Universität Braunschweig, Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie, Braunschweig, Germany.
Schneider KT; Technische Universität Braunschweig, Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie, Braunschweig, Germany.
Roth KDR; Technische Universität Braunschweig, Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie, Braunschweig, Germany.
Ruschig M; Technische Universität Braunschweig, Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie, Braunschweig, Germany.
Riese P; Technische Universität Braunschweig, Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie, Braunschweig, Germany.; Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Eschke K; Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Kim Y; Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Schäckermann D; Technische Universität Braunschweig, Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie, Braunschweig, Germany.
Pedotti M; Institute for Research in Biomedicine (IRB), Università della Svizzera italiana (USI), Bellinzona, Switzerland.
Kuhn P; YUMAB GmbH, Braunschweig, Germany.
Zock-Emmenthal S; Technische Universität Braunschweig, Institut für Genetik, Braunschweig, Germany.
Wöhrle J; BioCopy GmbH, Emmendingen, Germany.
Kilb N; BioCopy GmbH, Emmendingen, Germany.
Herz T; BioCopy GmbH, Emmendingen, Germany.
Becker M; Technische Universität Braunschweig, Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie, Braunschweig, Germany.
Grasshoff M; Helmholtz Centre for Infection Research, Research Group Innate Immunity and Infection, Braunschweig, Germany.
Wenzel EV; Technische Universität Braunschweig, Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie, Braunschweig, Germany.
Russo G; Technische Universität Braunschweig, Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie, Braunschweig, Germany.
Kröger A; Helmholtz Centre for Infection Research, Research Group Innate Immunity and Infection, Braunschweig, Germany.
Brunotte L; Westfälische Wilhelms-Universität Münster, Institut für Virologie (IVM), Münster, Germany.
Ludwig S; Westfälische Wilhelms-Universität Münster, Institut für Virologie (IVM), Münster, Germany.
Fühner V; Technische Universität Braunschweig, Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie, Braunschweig, Germany.
Krämer SD; BioCopy GmbH, Emmendingen, Germany.
Dübel S; Technische Universität Braunschweig, Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie, Braunschweig, Germany.
Varani L; Institute for Research in Biomedicine (IRB), Università della Svizzera italiana (USI), Bellinzona, Switzerland. .
Roth G; BioCopy GmbH, Emmendingen, Germany. .
Čičin-Šain L; Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany. .; Centre for Individualised Infection Medicine (CIIM), a joint venture of Helmholtz Centre for Infection Research and Medical School Hannover, Braunschweig, Germany. .
Schubert M; Technische Universität Braunschweig, Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie, Braunschweig, Germany. .
Hust M; Technische Universität Braunschweig, Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie, Braunschweig, Germany. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2021 Mar 11; Vol. 12 (1), pp. 1577. Date of Electronic Publication: 2021 Mar 11.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Angiotensin-Converting Enzyme 2/*immunology
Antibodies, Neutralizing/*genetics
Antibodies, Viral/*genetics
COVID-19/*immunology
SARS-CoV-2/*immunology
Spike Glycoprotein, Coronavirus/*immunology
Angiotensin-Converting Enzyme 2/chemistry ; Animals ; Antibodies, Neutralizing/isolation & purification ; Antibodies, Viral/isolation & purification ; Antibody Affinity ; COVID-19/epidemiology ; Cell Line ; Chlorocebus aethiops ; Gene Library ; Healthy Volunteers ; Host Microbial Interactions/immunology ; Humans ; Immunoglobulin G/genetics ; Immunoglobulin G/isolation & purification ; Models, Molecular ; Mutation ; Neutralization Tests ; Pandemics ; Peptide Library ; Protein Interaction Domains and Motifs ; Recombinant Proteins/genetics ; Recombinant Proteins/immunology ; SARS-CoV-2/genetics ; Spike Glycoprotein, Coronavirus/chemistry ; Vero Cells
SCR Organism :
SARS-CoV-2 variants
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies